MassChallenge Startups Create Impact


Startups Accelerated


Funding Raised


Revenue Generated


Jobs Created

Our startups

Be inspired. Search our startups.

Asan Therapeutics

Small immunomodulatory molecules are an emerging class of cancer therapies. Due to quick clearance by the body (1-2 hrs), 3 - 4 injections/month are required. This increases the risk of infection, the cancer spreading, and lowers patient adherence. Our novel drug delivery platform technology provides delayed release (3-100 days) to simplify the treatment to just one monthly injection. We will start with skin, breast and pancreatic cancer patients, resulting in an initial market of $27+B.
We use a novel technology to simplify treatment of cancer patients to receive only a single injection instead of several painful injections.

Connect with Asan Therapeutics

Asan Therapeutics


2021 Finalist BOS-96

Sub industry

Therapeutics (Pharma / Biotech)


Our mission is to equip bold entrepreneurs to disrupt the status quo and to create meaningful change.